Skip to content
Press Releases

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Veracyte Announces That Data From Multiple Studies Demonstrate “Real-World” Value of Afirma Genomic Sequencing Classifier in Thyroid Cancer Diagnosis
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 19, 2018-- Veracyte, Inc. (Nasdaq: VCYT) announced that early user-experience data from three independent studies demonstrate that the next-generation Afirma Genomic Sequencing Classifier (GSC) significantly increases the number of patients who can
View HTML
Toggle Summary Veracyte Launches Early Access Program for Envisia Genomic Classifier to Improve Diagnosis of IPF
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 17, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that it has launched an Early Access Program to begin making the Envisia Genomic Classifier available to patients being evaluated for interstitial lung diseases (ILD), including idiopathic
View HTML
Toggle Summary Veracyte Announces Launch of New Afirma Xpression Atlas at 2018 AACE Congress
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 16, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced the launch of the new Afirma Xpression Atlas, an RNA sequencing-based test that provides extensive genomic information to aid in surgery and treatment decisions for patients with potentially
View HTML
Toggle Summary Veracyte to Launch New Afirma Xpression Atlas and Present Platform Performance Data at AACE 2018 Meeting
Multiple Abstracts Showcasing “Real-World” Performance of the Afirma Genomic Sequencing Classifier also to be Presented SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 10, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that it will commercially launch its Afirma Xpression Atlas and present
View HTML
Toggle Summary *UPDATED WITH NEW TIME**: Veracyte to Present at the 2018 UBS Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 9, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson , chairman and chief executive officer, will present at the 2018 UBS Global Healthcare Conference on Wednesday, May 23, 2018 at 9:00 a.m. Eastern Time in New York, NY .
View HTML
Toggle Summary Veracyte Announces First Quarter 2018 Financial Results
Grew Revenue by 22%, to $20.0 Million Executed In-Network Contract with Anthem Company Raises 2018 Annual Revenue Guidance Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 1, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced financial results
View HTML
Toggle Summary Veracyte to Host Conference Call and Webcast to Discuss First Quarter 2018 Financial Results on Tuesday, May 1, 2018
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 17, 2018-- Veracyte, Inc. (Nasdaq: VCYT) announced today that it will report its first quarter 2018 financial results after the close of market on Tuesday, May 1, 2018 . Following the announcement, Veracyte will host a conference call and webcast
View HTML
Toggle Summary Veracyte Announces Precision Medicine Collaboration With Loxo Oncology
Agreement Leverages Veracyte’s New Afirma Xpression Atlas Platform SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 11, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced a research collaboration through which Loxo Oncology will access Veracyte’s new Afirma ® Xpression Atlas platform to
View HTML
Toggle Summary Veracyte Unveils Afirma Xpression Atlas Platform at ENDO 2018
RNA Sequencing-Based Platform Will Provide Extensive Genomic Content to Help Inform Surgery and Treatment Decisions for Patients with Suspected Thyroid Cancer SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 19, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that its soon-to-be-launched
View HTML
Toggle Summary Veracyte Announces New Data Suggesting Afirma GSC’s Ability to Help Significantly More Patients Avoid Unnecessary Thyroid Surgery
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 19, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that new data presented at ENDO 2018, the annual meeting of the Endocrine Society , suggest that the Afirma Genomic Sequencing Classifier (GSC) can help significantly more patients avoid
View HTML